The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice.
The most common hemoglobin disorder worldwide is sickle cell disease (SCD) caused by a point mutation in the adult β-globin gene. As a result, hemoglobin S production occurs leading to clinical symptoms including vaso-occlusive pain, organ damage, and a shortened lifespan. Hydroxyurea is the only FD...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0323550 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850265802704420864 |
|---|---|
| author | Mayuko Takezaki Biaoru Li Hongyan Xu Nikhil Patel Rudolf Lucas Ryan E Cerbone Sivanagireddy Koti Clifford L Hendrick Louis H Junker Betty S Pace |
| author_facet | Mayuko Takezaki Biaoru Li Hongyan Xu Nikhil Patel Rudolf Lucas Ryan E Cerbone Sivanagireddy Koti Clifford L Hendrick Louis H Junker Betty S Pace |
| author_sort | Mayuko Takezaki |
| collection | DOAJ |
| description | The most common hemoglobin disorder worldwide is sickle cell disease (SCD) caused by a point mutation in the adult β-globin gene. As a result, hemoglobin S production occurs leading to clinical symptoms including vaso-occlusive pain, organ damage, and a shortened lifespan. Hydroxyurea is the only FDA-approved fetal hemoglobin (HbF) inducer in the United States that ameliorates the clinical severity of SCD. Due to challenges with hydroxyurea, our study aimed to address the unmet need for the development of non-chemotherapeutic HbF inducers. We investigated the ability of CT-101, a Class 1 histone deacetylase inhibitor, to flip the γ-globin to β-globin switch in a humanized SCD mouse model. Pharmacokinetic parameters were assessed in CD-1 and Townes SCD mice after a single intraperitoneal drug dose. Similar drug uptake and half-life were observed in both animals. Subsequent studies in β-YAC mice expressing human γ-globin and β-globin genes established the optimal dose of CT-101 that induces HbF without peripheral blood toxicity. Subsequent confirmatory studies were conducted in the SCD mouse treated with intraperitoneal CT-101, demonstrating increases in F-cells, HbF, and γ-globin gene mRNA levels. Hydroxyurea combined with CT-101 significantly decreased spleen size and hemorrhagic infarcts and improved splenic extramedullary hematopoiesis. Our novel agent, CT-101, flipped the switch by activating γ-globin gene transcription and HbF protein synthesis in the preclinical SCD mouse model without significant toxicity in the peripheral blood. These findings support the development of an oral CT-101 formulation for clinical testing in SCD. |
| format | Article |
| id | doaj-art-ad171124393c411ea7ca80da762dbdc5 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-ad171124393c411ea7ca80da762dbdc52025-08-20T01:54:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01205e032355010.1371/journal.pone.0323550The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice.Mayuko TakezakiBiaoru LiHongyan XuNikhil PatelRudolf LucasRyan E CerboneSivanagireddy KotiClifford L HendrickLouis H JunkerBetty S PaceThe most common hemoglobin disorder worldwide is sickle cell disease (SCD) caused by a point mutation in the adult β-globin gene. As a result, hemoglobin S production occurs leading to clinical symptoms including vaso-occlusive pain, organ damage, and a shortened lifespan. Hydroxyurea is the only FDA-approved fetal hemoglobin (HbF) inducer in the United States that ameliorates the clinical severity of SCD. Due to challenges with hydroxyurea, our study aimed to address the unmet need for the development of non-chemotherapeutic HbF inducers. We investigated the ability of CT-101, a Class 1 histone deacetylase inhibitor, to flip the γ-globin to β-globin switch in a humanized SCD mouse model. Pharmacokinetic parameters were assessed in CD-1 and Townes SCD mice after a single intraperitoneal drug dose. Similar drug uptake and half-life were observed in both animals. Subsequent studies in β-YAC mice expressing human γ-globin and β-globin genes established the optimal dose of CT-101 that induces HbF without peripheral blood toxicity. Subsequent confirmatory studies were conducted in the SCD mouse treated with intraperitoneal CT-101, demonstrating increases in F-cells, HbF, and γ-globin gene mRNA levels. Hydroxyurea combined with CT-101 significantly decreased spleen size and hemorrhagic infarcts and improved splenic extramedullary hematopoiesis. Our novel agent, CT-101, flipped the switch by activating γ-globin gene transcription and HbF protein synthesis in the preclinical SCD mouse model without significant toxicity in the peripheral blood. These findings support the development of an oral CT-101 formulation for clinical testing in SCD.https://doi.org/10.1371/journal.pone.0323550 |
| spellingShingle | Mayuko Takezaki Biaoru Li Hongyan Xu Nikhil Patel Rudolf Lucas Ryan E Cerbone Sivanagireddy Koti Clifford L Hendrick Louis H Junker Betty S Pace The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice. PLoS ONE |
| title | The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice. |
| title_full | The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice. |
| title_fullStr | The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice. |
| title_full_unstemmed | The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice. |
| title_short | The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice. |
| title_sort | histone deacetylase inhibitor ct 101 flips the switch to fetal hemoglobin expression in sickle cell disease mice |
| url | https://doi.org/10.1371/journal.pone.0323550 |
| work_keys_str_mv | AT mayukotakezaki thehistonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT biaoruli thehistonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT hongyanxu thehistonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT nikhilpatel thehistonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT rudolflucas thehistonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT ryanecerbone thehistonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT sivanagireddykoti thehistonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT cliffordlhendrick thehistonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT louishjunker thehistonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT bettyspace thehistonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT mayukotakezaki histonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT biaoruli histonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT hongyanxu histonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT nikhilpatel histonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT rudolflucas histonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT ryanecerbone histonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT sivanagireddykoti histonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT cliffordlhendrick histonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT louishjunker histonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice AT bettyspace histonedeacetylaseinhibitorct101flipstheswitchtofetalhemoglobinexpressioninsicklecelldiseasemice |